Loading...
Market
Will Asceneuron successfully complete Phase 2 clinical trials for ASN51 by the end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Asceneuron's official press releases, clinical trial registries, and scientific publications
Story
Asceneuron Raises $100M in Series C for Alzheimer's Drug Development
Jul 16, 2024, 08:01 AM
Swiss biotech company Asceneuron announced it has raised $100 million in an oversubscribed Series C financing round. The funding, led by Novo Holdings, will be used to advance the clinical development of its Alzheimer's disease drug, targeting Tau protein aggregation. Investors include EQT Life Sciences, SofinnovaVC, and other notable backers. The raised capital will support the progression of Asceneuron's lead asset, ASN51, into Phase 2 clinical trials. The drug is being developed as an oral therapy. Professor Scheltens has joined the board to further bolster the company's expertise.
View original story
Similar markets
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%